Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease
Studies on serum leucine-rich alpha-2 glycoprotein (LRG) in inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), are scarce; the methods for estimating disease activity are less established, particularly for CD. This study is aimed at evaluating the utility o...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2021/8825374 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555225929482240 |
|---|---|
| author | Tetsuhiro Yoshimura Keiichi Mitsuyama Ryosuke Sakemi Hidetoshi Takedatsu Shinichiro Yoshioka Kotaro Kuwaki Atsushi Mori Shuhei Fukunaga Toshihiro Araki Masaru Morita Kozo Tsuruta Hiroshi Yamasaki Takuji Torimura |
| author_facet | Tetsuhiro Yoshimura Keiichi Mitsuyama Ryosuke Sakemi Hidetoshi Takedatsu Shinichiro Yoshioka Kotaro Kuwaki Atsushi Mori Shuhei Fukunaga Toshihiro Araki Masaru Morita Kozo Tsuruta Hiroshi Yamasaki Takuji Torimura |
| author_sort | Tetsuhiro Yoshimura |
| collection | DOAJ |
| description | Studies on serum leucine-rich alpha-2 glycoprotein (LRG) in inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), are scarce; the methods for estimating disease activity are less established, particularly for CD. This study is aimed at evaluating the utility of serum LRG as a potential inflammatory marker for IBD and to investigate the LRG gene expression in peripheral blood mononuclear cells (PBMCs) as a possible source of serum LRG. Overall, 98 patients with UC and 96 patients with CD were prospectively enrolled and clinically evaluated; 92 age-matched individuals served as the healthy controls. The blood samples were analyzed for serum LRG levels and routine laboratory parameters. Disease activity was assessed clinically and endoscopically. Finally, LRG gene expression in the PBMCs from a different cohort (41 patients with UC, 34 patients with CD, and 30 healthy controls) was examined. The serum LRG levels were higher during active disease than during inactive disease; additionally, serum LRG levels were positively correlated with clinical disease activity, C-reactive protein (CRP) levels, and other laboratory parameters in patients with UC and CD and with endoscopic disease activity in UC. UC and CD showed comparable areas under the curve (AUC) values for determining clinical remission and differentiating between endoscopic remission associated with LRG and CRP. The levels of LRG mRNA were also increased in PBMCs from patients with UC and CD and reflected disease activity. These data suggest that serum LRG, originated partially from PBMCs, is an inflammatory marker in UC and CD. A large-scale well-designed study should be conducted in the future to more accurately reveal the clinical significance of LRG in patients with IBD. |
| format | Article |
| id | doaj-art-696849b9281f4a3e8708ec33d14fbced |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-696849b9281f4a3e8708ec33d14fbced2025-02-03T05:49:18ZengWileyMediators of Inflammation0962-93511466-18612021-01-01202110.1155/2021/88253748825374Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel DiseaseTetsuhiro Yoshimura0Keiichi Mitsuyama1Ryosuke Sakemi2Hidetoshi Takedatsu3Shinichiro Yoshioka4Kotaro Kuwaki5Atsushi Mori6Shuhei Fukunaga7Toshihiro Araki8Masaru Morita9Kozo Tsuruta10Hiroshi Yamasaki11Takuji Torimura12Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, JapanDepartment of Gastroenterology, Tobata Kyoritsu Hospital, Kitakyushu, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, JapanStudies on serum leucine-rich alpha-2 glycoprotein (LRG) in inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), are scarce; the methods for estimating disease activity are less established, particularly for CD. This study is aimed at evaluating the utility of serum LRG as a potential inflammatory marker for IBD and to investigate the LRG gene expression in peripheral blood mononuclear cells (PBMCs) as a possible source of serum LRG. Overall, 98 patients with UC and 96 patients with CD were prospectively enrolled and clinically evaluated; 92 age-matched individuals served as the healthy controls. The blood samples were analyzed for serum LRG levels and routine laboratory parameters. Disease activity was assessed clinically and endoscopically. Finally, LRG gene expression in the PBMCs from a different cohort (41 patients with UC, 34 patients with CD, and 30 healthy controls) was examined. The serum LRG levels were higher during active disease than during inactive disease; additionally, serum LRG levels were positively correlated with clinical disease activity, C-reactive protein (CRP) levels, and other laboratory parameters in patients with UC and CD and with endoscopic disease activity in UC. UC and CD showed comparable areas under the curve (AUC) values for determining clinical remission and differentiating between endoscopic remission associated with LRG and CRP. The levels of LRG mRNA were also increased in PBMCs from patients with UC and CD and reflected disease activity. These data suggest that serum LRG, originated partially from PBMCs, is an inflammatory marker in UC and CD. A large-scale well-designed study should be conducted in the future to more accurately reveal the clinical significance of LRG in patients with IBD.http://dx.doi.org/10.1155/2021/8825374 |
| spellingShingle | Tetsuhiro Yoshimura Keiichi Mitsuyama Ryosuke Sakemi Hidetoshi Takedatsu Shinichiro Yoshioka Kotaro Kuwaki Atsushi Mori Shuhei Fukunaga Toshihiro Araki Masaru Morita Kozo Tsuruta Hiroshi Yamasaki Takuji Torimura Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease Mediators of Inflammation |
| title | Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease |
| title_full | Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease |
| title_fullStr | Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease |
| title_full_unstemmed | Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease |
| title_short | Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease |
| title_sort | evaluation of serum leucine rich alpha 2 glycoprotein as a new inflammatory biomarker of inflammatory bowel disease |
| url | http://dx.doi.org/10.1155/2021/8825374 |
| work_keys_str_mv | AT tetsuhiroyoshimura evaluationofserumleucinerichalpha2glycoproteinasanewinflammatorybiomarkerofinflammatoryboweldisease AT keiichimitsuyama evaluationofserumleucinerichalpha2glycoproteinasanewinflammatorybiomarkerofinflammatoryboweldisease AT ryosukesakemi evaluationofserumleucinerichalpha2glycoproteinasanewinflammatorybiomarkerofinflammatoryboweldisease AT hidetoshitakedatsu evaluationofserumleucinerichalpha2glycoproteinasanewinflammatorybiomarkerofinflammatoryboweldisease AT shinichiroyoshioka evaluationofserumleucinerichalpha2glycoproteinasanewinflammatorybiomarkerofinflammatoryboweldisease AT kotarokuwaki evaluationofserumleucinerichalpha2glycoproteinasanewinflammatorybiomarkerofinflammatoryboweldisease AT atsushimori evaluationofserumleucinerichalpha2glycoproteinasanewinflammatorybiomarkerofinflammatoryboweldisease AT shuheifukunaga evaluationofserumleucinerichalpha2glycoproteinasanewinflammatorybiomarkerofinflammatoryboweldisease AT toshihiroaraki evaluationofserumleucinerichalpha2glycoproteinasanewinflammatorybiomarkerofinflammatoryboweldisease AT masarumorita evaluationofserumleucinerichalpha2glycoproteinasanewinflammatorybiomarkerofinflammatoryboweldisease AT kozotsuruta evaluationofserumleucinerichalpha2glycoproteinasanewinflammatorybiomarkerofinflammatoryboweldisease AT hiroshiyamasaki evaluationofserumleucinerichalpha2glycoproteinasanewinflammatorybiomarkerofinflammatoryboweldisease AT takujitorimura evaluationofserumleucinerichalpha2glycoproteinasanewinflammatorybiomarkerofinflammatoryboweldisease |